Get started
Author

Konstantin Kazankov

Observed names: K Kazankov, K. Kazankov, Kazankov, K, Kazankov, Konstantin, Kazankov, Konstantin; id_orcid 0000-0002-8111-213X
Observed institutions: The University of Sydney, Inserm, Aarhus University, The Royal Free Hospital, Aarhus University Hospital, Seoul National University Hospital, Westmead Hospital, Sorbonne Université, Nutrition et obésité : approches systémiques, Westmead Institute for Medical Research, Regional Hospital Randers, Fondation pour l’innovation en Cadiométabolisme et Nutrition, National Health and Medical Research Council, Université Pierre-et-Marie-Curie, University College London, University of Bari Aldo Moro
ORCID: 0000-0002-8111-213X
Observed ORCID: 0000-0002-8111-213X
OpenAlex ID: A5064786401
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
2018 · Konstantin Kazankov, Simon Mark Dahl Jørgensen, et al. · Nature Reviews Gastroenterology & Hepatology · 941
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease
2019 · Chiara Rosso, Konstantin Kazankov, et al. · Journal of Hepatology · 217
PDF
Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects
2019 · Tea L Laursen, Christoffer A Hagemann, et al. · World Journal of Hepatology · 175
PDF
Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C
2014 · Konstantin Kazankov, Francisco Barrera, et al. · Hepatology · 172
PDF
Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging
2011 · Konstantin Kazankov, Peter Holland-Fischer, et al. · Liver International · 125
The macrophage activation marker sCD 163 is associated with morphological disease stages in patients with non‐alcoholic fatty liver disease
2016 · Konstantin Kazankov, Francisco Barrera, et al. · Liver International · 113
Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients
2015 · Mette J. Nielsen, Konstantin Kazankov, et al. · PLoS ONE · 67
PDF
Macrophage activation marker soluble CD 163 and non‐alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery
2015 · Konstantin Kazankov, Joan Tordjman, et al. · Journal of Gastroenterology and Hepatology · 60
The macrophage activation marker s CD 163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children
2014 · K. Kazankov, H. J. Møller, et al. · Pediatric Obesity · 60
Time‐dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct‐acting antiviral therapy of chronic hepatitis C
2019 · Tea Lund Laursen, Cecilie Brøckner Siggaard, et al. · Journal of Viral Hepatitis · 54
PDF
Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis
2021 · Rasmus Hvidbjerg Gantzel, Mikkel Breinholt Kjær, et al. · Frontiers in Medicine · 49
PDF
Evaluation of CirrhoCare® – a digital health solution for home management of individuals with cirrhosis
2022 · Konstantin Kazankov, Simone Novelli, et al. · Journal of Hepatology · 47
PDF
Single‐centre experience of the macrophage activation marker soluble (s)CD163 – associations with disease activity and treatment response in patients with autoimmune hepatitis
2016 · H. Grønbæk, M. Kreutzfeldt, et al. · Alimentary Pharmacology & Therapeutics · 46
Risk and Outcome of Venous and Arterial Thrombosis in Patients With Cirrhosis: A Danish Nation‐wide Cohort Study
2021 · Peter Jepsen, Elliot B. Tapper, et al. · Hepatology · 43
Hepatic macrophage activation predicts clinical decompensation in chronic liver disease
2013 · Anthony Rode, Amanda Nicoll, et al. · Gut · 40
Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury
2016 · M. J. Nielsen, M. A. Karsdal, et al. · Alimentary Pharmacology & Therapeutics · 39
PDF
Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma
2015 · Konstantin Kazankov, Anthony Rode, et al. · Scandinavian Journal of Clinical and Laboratory Investigation · 33
Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology
2018 · Tea Lund Laursen, Cecilie Brøckner Siggard, et al. · Scandinavian Journal of Gastroenterology · 31
Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease
2017 · Sidsel Rødgaard-Hansen, Alexis St. George, et al. · Scandinavian Journal of Clinical and Laboratory Investigation · 30
Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment
2017 · Tea Lund Laursen, Grace Lai‐Hung Wong, et al. · Journal of Gastroenterology and Hepatology · 29
Liver-related effects of chronic hepatitis C antiviral treatment
2020 · Tea L Laursen, Thomas D Sandahl, et al. · World Journal of Gastroenterology · 28
PDF
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis
2021 · Elisa Pose, Elsa Solà, et al. · Hepatology Communications · 27
PDF
High burden of coronary atherosclerosis in patients with cirrhosis
2017 · Konstantin Kazankov, Kim Munk, et al. · European Journal of Clinical Investigation · 22
The new digital era in decompensated cirrhosis
2024 · Kohilan Gananandan, Konstantin Kazankov, et al. · The Lancet Digital Health · 15
Macrophage markers and innate immunity in cirrhosis
2020 · Henning Grønbæk, Rasmus Hvidbjerg Gantzel, et al. · Journal of Hepatology · 14
PDF
Works count: 94
Citation count: 2,607
H-index: 22
I10-index: 29
Year
Topic
Type